Copper chelation therapy inhibits renal fibrosis by modulating copper transport proteins

Biofactors. 2022 Jul;48(4):934-945. doi: 10.1002/biof.1837. Epub 2022 Mar 24.

Abstract

The copper (Cu) transporter proteins play an important role in the maintenance of the Cu homeostasis in the body. Lysyl oxidase (LOX) proteins are involved in crosslinking of collagens and elastin molecules resulting in the establishment of extracellular matrix (ECM) and require Cu for their functional activity. Although there are few reports showing the protective effects of Cu chelators, the mechanism behind protection remains unknown. The present study investigated the role of Cu transporter proteins in renal fibrosis. We used tubular epithelial cells and three different animal models of renal injury to investigate the induction of Cu transporter proteins in renal injury with different etiology. We used disulfiram, clioquinol as two Cu chelators and ammonium tetrathiomolybdate as a standard Cu chelator. In addition, β-aminopropionitrile (BAPN) was used as a standard LOX inhibitor. We demonstrated that renal fibrosis is associated with the induction of Cu transporter proteins such as ATP7A and Copper Transporter 1 (CTR1) but the Cu overload did not induce renal fibrosis. In addition, the Cu chelators inhibited renal fibrosis by inhibiting the Cu transporter proteins.

Keywords: ATP7A; CTR1; Lysyl oxidase; TGF-β; copper transporters.

MeSH terms

  • Animals
  • Chelating Agents / pharmacology
  • Chelation Therapy
  • Copper Transport Proteins
  • Copper* / metabolism
  • Fibrosis
  • Kidney Diseases*

Substances

  • Chelating Agents
  • Copper Transport Proteins
  • Copper